Compounds > 2-amino-4-hydroxypteridine
Page last updated: 2024-10-15

2-amino-4-hydroxypteridine

Cross-References

ID SourceID
PubMed CID135398660
CHEMBL ID278009
CHEBI ID18265
CHEBI ID37105
CHEBI ID44992
SCHEMBL ID64320
MeSH IDM0049154

Synonyms (71)

Synonym
nsc170929
nsc-170929
CHEBI:18265 ,
CHEBI:37105
2-aminopteridin-4(1h)-one
2-amino-1h-pteridin-4-one
nsc 18696
einecs 218-799-1
nsc 11540
nsc 170929
pterin (van)
nsc18696
pteridoxamine
nsc11540
nsc-11540
2-amino-4(1h)-pteridinone
quinonoid dihydropterin, 2-amino-
4-oxopterin
4(1h)-pteridinone, 2-amino-
nsc-18696
2-amino-4(3h)-pteridinone
2-amino-4-pteridone
2-aminopteridin-4-ol
2-amino-4-pteridinol
4(3h)-pteridinone, 2-amino-
2-aminopteridin-4(3h)-one
inchi=1/c6h5n5o/c7-6-10-4-3(5(12)11-6)8-1-2-9-4/h1-2h,(h3,7,9,10,11,12
2236-60-4
2-amino-4-hydroxypteridine ,
2-amino-4-oxopteridine
C00715
pterin
pterine, ~95%
pterine
CHEBI:44992
OPREA1_553855
bdbm50125772
HMS1619F05
CHEMBL278009 ,
FT-0693892
pe0 ,
AKOS001714431
85ma24e1nh ,
unii-85ma24e1nh
FT-0634156
2-amino-4-hydroxy-pteridine
SCHEMBL64320
AKOS022636522
2-desamino-aminopterin
2-desaminoaminopterin
TS-00118
W-201928
AC-28118
DTXSID40176894
mfcd01456481
2-amino-3,4-dihydropteridin-4-one
pterine, >=97.0% (hplc)
938-42-1
2-amino-quinonoid dihydropterin
2-amino-3h-pteridin-4-one
4-oxo-2-aminopteridine
2-aminopteridin-4-one
Q386702
AMY25899
CS-0094341
cid 73000
2-amino-4-hydroxypteridine, 2-amino-4-oxodihydropteridine, pterin
2-amino-4,8-dihydropteridin-4-one
EN300-248741
?2-amino-4-hydroxy-1h-pteridine
SY074276
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pterin
2-amino-4-hydroxypteridineAny pteridine carrying amino and hydroxy substituents at positions 2 and 4 respectively.
pterin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Queuine tRNA-ribosyltransferaseZymomonas mobilis subsp. mobilis ZM4 = ATCC 31821Ki0.60000.60004.45008.3000AID228037
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID228037Inhibitory activity against eubacterial tRNA guanine transglycosylase (TGT) from Zymomonas mobilis2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's7 (63.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.46206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pteridines
[no description available]		8.4980azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
thymine
[no description available]		2.0510pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
xanthine
7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.		2.0610xanthineSaccharomyces cerevisiae metabolite
lumazine
lumazine: structure. 2,4-dihydroxypteridine : Any dihydroxypteridine in which the two hydroxy substituents are located at positions 2 and 4.. lumazine : A 2,4-dihydroxypteridine.		2.4202,4-dihydroxypteridine
luminol
Luminol: 5-Amino-2,3-dihydro-1,4-phthalazinedione. Substance that emits light on oxidation. It is used in chemical determinations.		2.0110
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		2.0610copper group element atom;
elemental silver		Escherichia coli metabolite
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.0610copper group element atom;
elemental gold
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.110benzenes;
phenyl acetates
isoluminol
isoluminol: chemiluminescent label		2.0110
isoalloxazine
isoalloxazine: structure		2.0510benzo[g]pteridine-2,4-dione
sepiapterin
sepiapterin: A substrate of sepiapterin reductase		2.0610sepiapterin
guanine
[no description available]		2.05102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
isoxanthopterin
[no description available]		2.420dihydroxypteridine
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		2.420nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
xanthopterin
[no description available]		2.7130
2-amino-4-hydroxy-6-formylpteridine
2-amino-4-hydroxy-6-formylpteridine: pteridine precursor in biosynthesis of dihydropteroate; structure. 6-formylpterin : Pterin carrying a formyl group at position 6.		2.0610aldehyde;
pterins		EC 1.17.3.2 (xanthine oxidase) inhibitor;
reactive oxygen species generator
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Retinal Degeneration
A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)		01.9310